img

Global Recombinant Vector Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Recombinant Vector Vaccines Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
Recombinant Vector Vaccines report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Vector Vaccines market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from For Adult and For Child are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Recombinant Vector Vaccines industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Recombinant Vector Vaccines key manufacturers include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. SANOFI PASTEUR S.A., Novartis, GSK are top 3 players and held % sales share in total in 2022.
Recombinant Vector Vaccines can be divided into Varicella, Influenza, Polio and Hepatitis A, etc. Varicella is the mainstream product in the market, accounting for % sales share globally in 2022.
Recombinant Vector Vaccines is widely used in various fields, such as For Adult and For Child, etc. For Adult provides greatest supports to the Recombinant Vector Vaccines industry development. In 2022, global % sales of Recombinant Vector Vaccines went into For Adult filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Vector Vaccines market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, tetanus
Pneumococcal
Others

Segment by Application


For Adult
For Child

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Recombinant Vector Vaccines market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Vector Vaccines, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Vector Vaccines industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Vector Vaccines in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Vector Vaccines introduction, etc. Recombinant Vector Vaccines Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Vector Vaccines market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Recombinant Vector Vaccines Market Overview
1.1 Recombinant Vector Vaccines Product Overview
1.2 Recombinant Vector Vaccines Market Segment by Type
1.2.1 Varicella
1.2.2 Influenza
1.2.3 Polio
1.2.4 Hepatitis A
1.2.5 Rabies
1.2.6 BCG
1.2.7 Hepatitis B
1.2.8 Pertussis, Diphtheria, tetanus
1.2.9 Pneumococcal
1.2.10 Others
1.3 Global Recombinant Vector Vaccines Market Size by Type
1.3.1 Global Recombinant Vector Vaccines Market Size Overview by Type (2024-2034)
1.3.2 Global Recombinant Vector Vaccines Historic Market Size Review by Type (2024-2024)
1.3.3 Global Recombinant Vector Vaccines Forecasted Market Size by Type (2024-2034)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Recombinant Vector Vaccines Sales Breakdown by Type (2024-2024)
1.4.2 Europe Recombinant Vector Vaccines Sales Breakdown by Type (2024-2024)
1.4.3 Asia-Pacific Recombinant Vector Vaccines Sales Breakdown by Type (2024-2024)
1.4.4 Latin America Recombinant Vector Vaccines Sales Breakdown by Type (2024-2024)
1.4.5 Middle East and Africa Recombinant Vector Vaccines Sales Breakdown by Type (2024-2024)
2 Global Recombinant Vector Vaccines Market Competition by Company
2.1 Global Top Players by Recombinant Vector Vaccines Sales (2024-2024)
2.2 Global Top Players by Recombinant Vector Vaccines Revenue (2024-2024)
2.3 Global Top Players by Recombinant Vector Vaccines Price (2024-2024)
2.4 Global Top Manufacturers Recombinant Vector Vaccines Manufacturing Base Distribution, Sales Area, Product Type
2.5 Recombinant Vector Vaccines Market Competitive Situation and Trends
2.5.1 Recombinant Vector Vaccines Market Concentration Rate (2024-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Recombinant Vector Vaccines Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Vector Vaccines as of 2022)
2.7 Date of Key Manufacturers Enter into Recombinant Vector Vaccines Market
2.8 Key Manufacturers Recombinant Vector Vaccines Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Recombinant Vector Vaccines Status and Outlook by Region
3.1 Global Recombinant Vector Vaccines Market Size and CAGR by Region: 2024 VS 2022 VS 2034
3.2 Global Recombinant Vector Vaccines Historic Market Size by Region
3.2.1 Global Recombinant Vector Vaccines Sales in Volume by Region (2024-2024)
3.2.2 Global Recombinant Vector Vaccines Sales in Value by Region (2024-2024)
3.2.3 Global Recombinant Vector Vaccines Sales (Volume & Value) Price and Gross Margin (2024-2024)
3.3 Global Recombinant Vector Vaccines Forecasted Market Size by Region
3.3.1 Global Recombinant Vector Vaccines Sales in Volume by Region (2024-2034)
3.3.2 Global Recombinant Vector Vaccines Sales in Value by Region (2024-2034)
3.3.3 Global Recombinant Vector Vaccines Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Recombinant Vector Vaccines by Application
4.1 Recombinant Vector Vaccines Market Segment by Application
4.1.1 For Adult
4.1.2 For Child
4.2 Global Recombinant Vector Vaccines Market Size by Application
4.2.1 Global Recombinant Vector Vaccines Market Size Overview by Application (2024-2034)
4.2.2 Global Recombinant Vector Vaccines Historic Market Size Review by Application (2024-2024)
4.2.3 Global Recombinant Vector Vaccines Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Recombinant Vector Vaccines Sales Breakdown by Application (2024-2024)
4.3.2 Europe Recombinant Vector Vaccines Sales Breakdown by Application (2024-2024)
4.3.3 Asia-Pacific Recombinant Vector Vaccines Sales Breakdown by Application (2024-2024)
4.3.4 Latin America Recombinant Vector Vaccines Sales Breakdown by Application (2024-2024)
4.3.5 Middle East and Africa Recombinant Vector Vaccines Sales Breakdown by Application (2024-2024)
5 North America Recombinant Vector Vaccines by Country
5.1 North America Recombinant Vector Vaccines Historic Market Size by Country
5.1.1 North America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
5.1.2 North America Recombinant Vector Vaccines Sales in Volume by Country (2024-2024)
5.1.3 North America Recombinant Vector Vaccines Sales in Value by Country (2024-2024)
5.2 North America Recombinant Vector Vaccines Forecasted Market Size by Country
5.2.1 North America Recombinant Vector Vaccines Sales in Volume by Country (2024-2034)
5.2.2 North America Recombinant Vector Vaccines Sales in Value by Country (2024-2034)
6 Europe Recombinant Vector Vaccines by Country
6.1 Europe Recombinant Vector Vaccines Historic Market Size by Country
6.1.1 Europe Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
6.1.2 Europe Recombinant Vector Vaccines Sales in Volume by Country (2024-2024)
6.1.3 Europe Recombinant Vector Vaccines Sales in Value by Country (2024-2024)
6.2 Europe Recombinant Vector Vaccines Forecasted Market Size by Country
6.2.1 Europe Recombinant Vector Vaccines Sales in Volume by Country (2024-2034)
6.2.2 Europe Recombinant Vector Vaccines Sales in Value by Country (2024-2034)
7 Asia-Pacific Recombinant Vector Vaccines by Region
7.1 Asia-Pacific Recombinant Vector Vaccines Historic Market Size by Region
7.1.1 Asia-Pacific Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Region: 2024 VS 2022 VS 2034
7.1.2 Asia-Pacific Recombinant Vector Vaccines Sales in Volume by Region (2024-2024)
7.1.3 Asia-Pacific Recombinant Vector Vaccines Sales in Value by Region (2024-2024)
7.2 Asia-Pacific Recombinant Vector Vaccines Forecasted Market Size by Region
7.2.1 Asia-Pacific Recombinant Vector Vaccines Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Recombinant Vector Vaccines Sales in Value by Region (2024-2034)
8 Latin America Recombinant Vector Vaccines by Country
8.1 Latin America Recombinant Vector Vaccines Historic Market Size by Country
8.1.1 Latin America Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
8.1.2 Latin America Recombinant Vector Vaccines Sales in Volume by Country (2024-2024)
8.1.3 Latin America Recombinant Vector Vaccines Sales in Value by Country (2024-2024)
8.2 Latin America Recombinant Vector Vaccines Forecasted Market Size by Country
8.2.1 Latin America Recombinant Vector Vaccines Sales in Volume by Country (2024-2034)
8.2.2 Latin America Recombinant Vector Vaccines Sales in Value by Country (2024-2034)
9 Middle East and Africa Recombinant Vector Vaccines by Country
9.1 Middle East and Africa Recombinant Vector Vaccines Historic Market Size by Country
9.1.1 Middle East and Africa Recombinant Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2024 VS 2022 VS 2034
9.1.2 Middle East and Africa Recombinant Vector Vaccines Sales in Volume by Country (2024-2024)
9.1.3 Middle East and Africa Recombinant Vector Vaccines Sales in Value by Country (2024-2024)
9.2 Middle East and Africa Recombinant Vector Vaccines Forecasted Market Size by Country
9.2.1 Middle East and Africa Recombinant Vector Vaccines Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Recombinant Vector Vaccines Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 SANOFI PASTEUR S.A.
10.1.1 SANOFI PASTEUR S.A. Company Information
10.1.2 SANOFI PASTEUR S.A. Introduction and Business Overview
10.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Products Offered
10.1.5 SANOFI PASTEUR S.A. Recent Development
10.2 Novartis
10.2.1 Novartis Company Information
10.2.2 Novartis Introduction and Business Overview
10.2.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.2.4 Novartis Recombinant Vector Vaccines Products Offered
10.2.5 Novartis Recent Development
10.3 GSK
10.3.1 GSK Company Information
10.3.2 GSK Introduction and Business Overview
10.3.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.3.4 GSK Recombinant Vector Vaccines Products Offered
10.3.5 GSK Recent Development
10.4 CNBG
10.4.1 CNBG Company Information
10.4.2 CNBG Introduction and Business Overview
10.4.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.4.4 CNBG Recombinant Vector Vaccines Products Offered
10.4.5 CNBG Recent Development
10.5 ChengDa Bio
10.5.1 ChengDa Bio Company Information
10.5.2 ChengDa Bio Introduction and Business Overview
10.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.5.4 ChengDa Bio Recombinant Vector Vaccines Products Offered
10.5.5 ChengDa Bio Recent Development
10.6 Changsheng Life
10.6.1 Changsheng Life Company Information
10.6.2 Changsheng Life Introduction and Business Overview
10.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.6.4 Changsheng Life Recombinant Vector Vaccines Products Offered
10.6.5 Changsheng Life Recent Development
10.7 Zhifei
10.7.1 Zhifei Company Information
10.7.2 Zhifei Introduction and Business Overview
10.7.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.7.4 Zhifei Recombinant Vector Vaccines Products Offered
10.7.5 Zhifei Recent Development
10.8 SINOVAC BIOTECH
10.8.1 SINOVAC BIOTECH Company Information
10.8.2 SINOVAC BIOTECH Introduction and Business Overview
10.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.8.4 SINOVAC BIOTECH Recombinant Vector Vaccines Products Offered
10.8.5 SINOVAC BIOTECH Recent Development
10.9 NuoCheng Bio
10.9.1 NuoCheng Bio Company Information
10.9.2 NuoCheng Bio Introduction and Business Overview
10.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.9.4 NuoCheng Bio Recombinant Vector Vaccines Products Offered
10.9.5 NuoCheng Bio Recent Development
10.10 Hualan Bio
10.10.1 Hualan Bio Company Information
10.10.2 Hualan Bio Introduction and Business Overview
10.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.10.4 Hualan Bio Recombinant Vector Vaccines Products Offered
10.10.5 Hualan Bio Recent Development
10.11 Kangtai
10.11.1 Kangtai Company Information
10.11.2 Kangtai Introduction and Business Overview
10.11.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2024-2024)
10.11.4 Kangtai Recombinant Vector Vaccines Products Offered
10.11.5 Kangtai Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Recombinant Vector Vaccines Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Recombinant Vector Vaccines Industrial Chain Analysis
11.4 Recombinant Vector Vaccines Market Dynamics
11.4.1 Recombinant Vector Vaccines Industry Trends
11.4.2 Recombinant Vector Vaccines Market Drivers
11.4.3 Recombinant Vector Vaccines Market Challenges
11.4.4 Recombinant Vector Vaccines Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Recombinant Vector Vaccines Distributors
12.3 Recombinant Vector Vaccines Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of Varicella
Table 2. Major Company of Influenza
Table 3. Major Company of Polio
Table 4. Major Company of Hepatitis A
Table 5. Major Company of Rabies
Table 6. Major Company of BCG
Table 7. Major Company of Hepatitis B
Table 8. Major Company of Pertussis, Diphtheria, tetanus
Table 9. Major Company of Pneumococcal
Table 10. Major Company of Others
Table 11. Global Recombinant Vector Vaccines Sales by Type 2024 VS 2022 VS 2034 (US$ Million)
Table 12. Global Recombinant Vector Vaccines Sales by Type (2024-2024) & (K Doses)
Table 13. Global Recombinant Vector Vaccines Sales Market Share in Volume by Type (2024-2024)
Table 14. Global Recombinant Vector Vaccines Sales by Type (2024-2024) & (US& Million)
Table 15. Global Recombinant Vector Vaccines Market Share in Value by Type (2024-2024)
Table 16. Global Recombinant Vector Vaccines Price by Type (2024-2024) & (USD/Dose)
Table 17. Global Recombinant Vector Vaccines Sales by Type (2024-2034) & (K Doses)
Table 18. Global Recombinant Vector Vaccines Sales Market Share in Volume by Type (2024-2034)
Table 19. Global Recombinant Vector Vaccines Sales by Type (2024-2034) & (US$ Million)
Table 20. Global Recombinant Vector Vaccines Sales Market Share in Value by Type (2024-2034)
Table 21. Global Recombinant Vector Vaccines Price by Type (2024-2034) & (USD/Dose)
Table 22. North America Recombinant Vector Vaccines Sales by Type (2024-2024) & (K Doses)
Table 23. North America Recombinant Vector Vaccines Sales by Type (2024-2024) & (US$ Million)
Table 24. Europe Recombinant Vector Vaccines Sales (K Doses) by Type (2024-2024)
Table 25. Europe Recombinant Vector Vaccines Sales by Type (2024-2024) & (US$ Million)
Table 26. Asia-Pacific Recombinant Vector Vaccines Sales (K Doses) by Type (2024-2024)
Table 27. Asia-Pacific Recombinant Vector Vaccines Sales by Type (2024-2024) & (US$ Million)
Table 28. Latin America Recombinant Vector Vaccines Sales (K Doses) by Type (2024-2024)
Table 29. Latin America Recombinant Vector Vaccines Sales by Type (2024-2024) & (US$ Million)
Table 30. Middle East and Africa Recombinant Vector Vaccines Sales (K Doses) by Type (2024-2024)
Table 31. Middle East and Africa Recombinant Vector Vaccines Sales by Type (2024-2024) & (US$ Million)
Table 32. Global Recombinant Vector Vaccines Sales by Company (2024-2024) & (K Doses)
Table 33. Global Recombinant Vector Vaccines Sales Share by Company (2024-2024)
Table 34. Global Recombinant Vector Vaccines Revenue by Company (2024-2024) & (US$ Million)
Table 35. Global Recombinant Vector Vaccines Revenue Share by Company (2024-2024)
Table 36. Global Market Recombinant Vector Vaccines Price by Company (2024-2024) & (USD/Dose)
Table 37. Global Recombinant Vector Vaccines Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 38. Global Recombinant Vector Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 39. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Recombinant Vector Vaccines as of 2022)
Table 40. Date of Key Manufacturers Enter into Recombinant Vector Vaccines Market
Table 41. Key Manufacturers Recombinant Vector Vaccines Product Type
Table 42. Mergers & Acquisitions, Expansion Plans
Table 43. Global Recombinant Vector Vaccines Market Size Comparison by Region (US$ Million): 2024 VS 2022 VS 2034
Table 44. Global Recombinant Vector Vaccines Sales by Region (2024-2024) & (K Doses)
Table 45. Global Recombinant Vector Vaccines Sales Market Share in Volume by Region (2024-2024)
Table 46. Global Recombinant Vector Vaccines Sales by Region (2024-2024) & (US$ Million)
Table 47. Global Recombinant Vector Vaccines Sales Market Share in Value by Region (2024-2024)
Table 48. Global Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2024-2024)
Table 49. Global Recombinant Vector Vaccines Sales by Region (2024-2034) & (K Doses)
Table 50. Global Recombinant Vector Vaccines Sales Market Share in Volume by Region (2024-2034)
Table 51. Global Recombinant Vector Vaccines Sales by Region (2024-2034) & (US$ Million)
Table 52. Global Recombinant Vector Vaccines Sales Market Share in Value by Region (2024-2034)
Table 53. Global Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2024-2034)
Table 54. Global Recombinant Vector Vaccines Sales by Application: 2024 VS 2022 VS 2034 (US$ Million)
Table 55. Global Recombinant Vector Vaccines Sales by Application (2024-2024) & (K Doses)
Table 56. Global Recombinant Vector Vaccines Sales Market Share in Volume by Application (2024-2024)
Table 57. Global Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 58. Global Recombinant Vector Vaccines Sales Market Share in Value by Application (2024-2024)
Table 59. Global Recombinant Vector Vaccines Price by Application (2024-2024) & (USD/Dose)
Table 60. Global Recombinant Vector Vaccines Sales by Application (2024-2034) & (K Doses)
Table 61. Global Recombinant Vector Vaccines Sales Market Share in Volume by Application (2024-2034)
Table 62. Global Recombinant Vector Vaccines Sales by Application (2024-2034) & (US$ Million)
Table 63. Global Recombinant Vector Vaccines Sales Market Share in Value by Application (2024-2034)
Table 64. Global Recombinant Vector Vaccines Price by Application (2024-2034) & (USD/Dose)
Table 65. North America Recombinant Vector Vaccines Sales by Application (2024-2024) (K Doses)
Table 66. North America Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 67. Europe Recombinant Vector Vaccines Sales by Application (2024-2024) (K Doses)
Table 68. Europe Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 69. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2024-2024) (K Doses)
Table 70. Asia-Pacific Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 71. Latin America Recombinant Vector Vaccines Sales by Application (2024-2024) (K Doses)
Table 72. Latin America Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 73. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2024-2024) (K Doses)
Table 74. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2024-2024) & (US$ Million)
Table 75. North America Recombinant Vector Vaccines Sales by Country (2024-2024) & (K Doses)
Table 76. North America Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2024)
Table 77. North America Recombinant Vector Vaccines Sales by Country (2024-2024) & (US$ Million)
Table 78. North America Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2024)
Table 79. North America Recombinant Vector Vaccines Sales by Country (2024-2034) & (K Doses)
Table 80. North America Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2034)
Table 81. North America Recombinant Vector Vaccines Sales by Country (2024-2034) & (US$ Million)
Table 82. North America Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2034)
Table 83. Europe Recombinant Vector Vaccines Sales by Country (2024-2024) & (K Doses)
Table 84. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2024)
Table 85. Europe Recombinant Vector Vaccines Sales by Country (2024-2024) & (US$ Million)
Table 86. Europe Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2024)
Table 87. Europe Recombinant Vector Vaccines Sales by Country (2024-2034) & (K Doses)
Table 88. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2034)
Table 89. Europe Recombinant Vector Vaccines Sales by Country (2024-2034) & (US$ Million)
Table 90. Europe Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2034)
Table 91. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2024-2024) & (K Doses)
Table 92. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Region (2024-2024)
Table 93. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2024-2024) & (US$ Million)
Table 94. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Region (2024-2024)
Table 95. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2024-2034) & (K Doses)
Table 96. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Region (2024-2034)
Table 97. Asia-Pacific Recombinant Vector Vaccines Sales by Region (2024-2034) & (US$ Million)
Table 98. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Region (2024-2034)
Table 99. Latin America Recombinant Vector Vaccines Sales by Country (2024-2024) & (K Doses)
Table 100. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2024)
Table 101. Latin America Recombinant Vector Vaccines Sales by Country (2024-2024) & (US$ Million)
Table 102. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2024)
Table 103. Latin America Recombinant Vector Vaccines Sales by Country (2024-2034) & (K Doses)
Table 104. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2034)
Table 105. Latin America Recombinant Vector Vaccines Sales by Country (2024-2034) & (US$ Million)
Table 106. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2034)
Table 107. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2024-2024) & (K Doses)
Table 108. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2024)
Table 109. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2024-2024) & (US$ Million)
Table 110. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2024)
Table 111. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2024-2034) & (K Doses)
Table 112. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Volume by Country (2024-2034)
Table 113. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2024-2034) & (US$ Million)
Table 114. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Country (2024-2034)
Table 115. SANOFI PASTEUR S.A. Company Information
Table 116. SANOFI PASTEUR S.A. Introduction and Business Overview
Table 117. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 118. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product
Table 119. SANOFI PASTEUR S.A. Recent Development
Table 120. Novartis Company Information
Table 121. Novartis Introduction and Business Overview
Table 122. Novartis Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 123. Novartis Recombinant Vector Vaccines Product
Table 124. Novartis Recent Development
Table 125. GSK Company Information
Table 126. GSK Introduction and Business Overview
Table 127. GSK Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 128. GSK Recombinant Vector Vaccines Product
Table 129. GSK Recent Development
Table 130. CNBG Company Information
Table 131. CNBG Introduction and Business Overview
Table 132. CNBG Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 133. CNBG Recombinant Vector Vaccines Product
Table 134. CNBG Recent Development
Table 135. ChengDa Bio Company Information
Table 136. ChengDa Bio Introduction and Business Overview
Table 137. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 138. ChengDa Bio Recombinant Vector Vaccines Product
Table 139. ChengDa Bio Recent Development
Table 140. Changsheng Life Company Information
Table 141. Changsheng Life Introduction and Business Overview
Table 142. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 143. Changsheng Life Recombinant Vector Vaccines Product
Table 144. Changsheng Life Recent Development
Table 145. Zhifei Company Information
Table 146. Zhifei Introduction and Business Overview
Table 147. Zhifei Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 148. Zhifei Recombinant Vector Vaccines Product
Table 149. Zhifei Recent Development
Table 150. SINOVAC BIOTECH Company Information
Table 151. SINOVAC BIOTECH Introduction and Business Overview
Table 152. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 153. SINOVAC BIOTECH Recombinant Vector Vaccines Product
Table 154. SINOVAC BIOTECH Recent Development
Table 155. NuoCheng Bio Company Information
Table 156. NuoCheng Bio Introduction and Business Overview
Table 157. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 158. NuoCheng Bio Recombinant Vector Vaccines Product
Table 159. NuoCheng Bio Recent Development
Table 160. Hualan Bio Company Information
Table 161. Hualan Bio Introduction and Business Overview
Table 162. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 163. Hualan Bio Recombinant Vector Vaccines Product
Table 164. Hualan Bio Recent Development
Table 165. Kangtai Company Information
Table 166. Kangtai Introduction and Business Overview
Table 167. Kangtai Recombinant Vector Vaccines Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2024-2024)
Table 168. Kangtai Recombinant Vector Vaccines Product
Table 169. Kangtai Recent Development
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Recombinant Vector Vaccines Market Trends
Table 173. Recombinant Vector Vaccines Market Drivers
Table 174. Recombinant Vector Vaccines Market Challenges
Table 175. Recombinant Vector Vaccines Market Restraints
Table 176. Recombinant Vector Vaccines Distributors List
Table 177. Recombinant Vector Vaccines Downstream Customers
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Vector Vaccines Product Picture
Figure 2. Global Recombinant Vector Vaccines Market Size, 2024 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Recombinant Vector Vaccines Market Size Status and Outlook (2024-2034) & (US$ Million)
Figure 4. Global Recombinant Vector Vaccines Sales Status and Outlook (2024-2034) & (K Doses)
Figure 5. Product Picture of Varicella
Figure 6. Global Varicella Sales YoY Growth (2024-2034) & (K Doses)
Figure 7. Product Picture of Influenza
Figure 8. Global Influenza Sales YoY Growth (2024-2034) & (K Doses)
Figure 9. Product Picture of Polio
Figure 10. Global Polio Sales YoY Growth (2024-2034) & (K Doses)
Figure 11. Product Picture of Hepatitis A
Figure 12. Global Hepatitis A Sales YoY Growth (2024-2034) & (K Doses)
Figure 13. Product Picture of Rabies
Figure 14. Global Rabies Sales YoY Growth (2024-2034) & (K Doses)
Figure 15. Product Picture of BCG
Figure 16. Global BCG Sales YoY Growth (2024-2034) & (K Doses)
Figure 17. Product Picture of Hepatitis B
Figure 18. Global Hepatitis B Sales YoY Growth (2024-2034) & (K Doses)
Figure 19. Product Picture of Pertussis, Diphtheria, tetanus
Figure 20. Global Pertussis, Diphtheria, tetanus Sales YoY Growth (2024-2034) & (K Doses)
Figure 21. Product Picture of Pneumococcal
Figure 22. Global Pneumococcal Sales YoY Growth (2024-2034) & (K Doses)
Figure 23. Product Picture of Others
Figure 24. Global Others Sales YoY Growth (2024-2034) & (K Doses)
Figure 25. Global Recombinant Vector Vaccines Sales by Type (2024-2034) & (US$ Million)
Figure 26. Global Recombinant Vector Vaccines Sales Market Share by Type in 2022 & 2034
Figure 27. North America Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2022
Figure 28. North America Recombinant Vector Vaccines Sales Market Share in Value by Type in 2022
Figure 29. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2022
Figure 30. Europe Recombinant Vector Vaccines Sales Market Share in Value by Type in 2022
Figure 31. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2022
Figure 32. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Type in 2022
Figure 33. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2022
Figure 34. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Type in 2022
Figure 35. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Volume by Type in 2022
Figure 36. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Type in 2022
Figure 37. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Vector Vaccines Sales in 2022
Figure 38. The 5 and 10 Largest Manufacturers in the World: Market Share by Recombinant Vector Vaccines Revenue in 2022
Figure 39. Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2024 VS 2022
Figure 40. Product Picture of For Adult
Figure 41. Global For Adult Sales YoY Growth (2024-2034) & (K Doses)
Figure 42. Product Picture of For Child
Figure 43. Global For Child Sales YoY Growth (2024-2034) & (K Doses)
Figure 44. Global Recombinant Vector Vaccines Sales by Application (2024-2034) & (US$ Million)
Figure 45. Global Recombinant Vector Vaccines Sales Market Share by Application in 2022 & 2034
Figure 46. North America Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2022
Figure 47. North America Recombinant Vector Vaccines Sales Market Share in Value by Application in 2022
Figure 48. Europe Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2022
Figure 49. Europe Recombinant Vector Vaccines Sales Market Share in Value by Application in 2022
Figure 50. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2022
Figure 51. Asia-Pacific Recombinant Vector Vaccines Sales Market Share in Value by Application in 2022
Figure 52. Latin America Recombinant Vector Vaccines Sales Market Share in Volume by Application in 2022
Figure 53. Latin America Recombinant Vector Vaccines Sales Market Share in Value by Application in 2022
Figure 54. Middle East and Africa Recombinant Vector Vaccines Sales Market Share in Value by Application in 2022
Figure 55. Key Raw Materials Price
Figure 56. Recombinant Vector Vaccines Manufacturing Cost Structure
Figure 57. Recombinant Vector Vaccines Industrial Chain Analysis
Figure 58. Channels of Distribution
Figure 59. Distributors Profiles
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries